Read Time:13 Second
While Eli Lilly and Novo Nordisk dominate the obesity-drug market, there’s a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, analysts say.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
